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Abstract: Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic 
disorders found in women, affecting approximately 105 million women worldwide. It is charac-
terized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either 
clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has 
long been a cornerstone of care for women with PCOS. COC therapy often provides clinical 
improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. 
One of the main issues in COC therapy is choosing the most appropriate progestin component 
to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has 
shown beneﬁ  t in the PCOS population when used in conjunction with ethinyl estradiol. We 
now review the role of COCs in PCOS, focusing speciﬁ  cally on drospirenone. Controversy 
over metabolic effects of COCs in PCOS is also discussed.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic 
disorders found in women. While the deﬁ  nition remains a point of controversy for 
some, PCOS is characterized by ovulatory dysfunction, usually presenting as oli-
gomenorrhea or amenorrhea, and either clinical or biochemical hyperandrogenism 
(Azziz et al 2006). The hyperandrogenism can result in hirsutism, oligo-amenorrhea, 
acne, and alopecia.
The prevalence of PCOS (based on the NIH 1990 criteria) in women of reproductive 
age is approximately 6.5%–8.0% (Michelmore et al 1999). This encompasses approxi-
mately 5 million women in the United States and 105 million women worldwide.
Clinically, PCOS is a heterogeneous disorder of functional androgen excess and 
the features of PCOS can run through a spectrum of severity. The clinical features 
may differ according to ethnicity, environmental factors, and medical co-morbidities 
(Table 1). Most features can be elicited by performing a precise history and physical 
examination.
The primary aspects of PCOS that require treatment are oligo-amenorrhea, 
hyperandrogenism, and metabolic concerns such as insulin resistance (Lobo 2006). 
While the majority of these patients show functional hyperandrogenism clinically, 
studies have found conﬂ  icting results (Pugeat et al 1993; Knochenhauer et al 1998; 
Legro et al 1998; Laven et al 2002; Azziz et al 2006) regarding absolute androgen 
levels. The ovaries are the primary site of implication in excessive production of 
androgens in PCOS. Theca cells (under the inﬂ  uence of lutenizing hormone [LH]) are 
overactive in steroidogenesis, subsequently providing excess androgens to function 
as a substrate for estradiol production through the process of aromatization (Azziz 
et al 2006). LH hypersecretion by the pituitary gland may be present or concentra-
tions of LH may be elevated due to increased amplitude and frequency of LH pulse. Therapeutics and Clinical Risk Management 2008:4(2) 488
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This is most often accompanied by a decrease in circulating 
follicle stimulating hormone (FSH). Both the LH and the 
FSH proﬁ  les are thought secondary to a fundamental increase 
in GnRH from the hypothalamus which ultimately favors 
the gene expression of LHb over FSHb (Azziz et al 2006). 
Insulin resistance with compensatory increases in circulating 
insulin levels may be present as well. The biochemical 
abnormalities noted above often result in anovulation. 
PCOS is the most common cause of anovulatory infertility 
(Laven et al 2002).
Hirsutism, or excessive hair growth in a male-like pattern, 
can be observed in approximately 75% of women with PCOS 
of white or black race (Azziz et al 2004). Areas of excessive 
hair growth include the face, anterior chest, midline abdomen 
area, and pubic region. There can be signiﬁ  cant variation in 
presentation of hirsutism depending on genetics and race. 
Clinical assessment is based on a visual scoring system 
(Ferriman-Gallwey 1961). Therapies for treating hair growth 
range from cosmetic procedures, such as laser therapy, 
to medications. Antiandrogens, including spironolactone, 
cyproterone acetate (CPA), ﬂ  utamide, and ﬁ  nasteride, are 
commonly prescribed for this condition, often in conjunction 
with other therapies, such as oral contraceptives (Venturoli 
et al 1999; Moghetti et al 2000).
Oligo-amenorrhea and the resultant fertility problems 
can be treated with agents such as, clomiphene, letrazole, 
metformin, and gonadotropin therapy, which induce ovula-
tion. This mode of treatment takes into account the concept 
that androgenic problems typical in women with PCOS are 
an effect of concomitant metabolic problems such as insulin 
insensitivity. Thus, drugs that treat the insulin insensitivity, 
such as metformin, should also be beneﬁ  cial in the treatment 
of hyperandrogenism and restore ovulation in women suf-
fering from PCOS. Another common mode of treatment of 
hyperandrogenism related to PCOS is oral contraceptives 
(used to suppress ovarian activity) often in conjunction with 
an anti-androgen agent (Lobo 2006).
Oral contraceptives in PCOS
Combined oral contraceptives (COC) are a common treat-
ment for PCOS and have a long history of use in this group 
of patients. Adolescents and women with PCOS have a 
number of different clinical symptoms that play a role in 
their daily quality of life. Excessive hair growth, irregular 
and unpredictable menses, acne and weight gain are all part 
of the clinical constellation seen in this population. COC 
has long been considered a ﬁ  rst line of therapy for women 
experiencing these symptoms and who do not wish to get 
pregnant. Publications from the 1960s (Mauvais-Jarvis et al 
1965) reported the inhibition of androgens with the use of 
“ovulation inhibitors”. Since then multiple reports have 
conﬁ  rmed this ﬁ  nding particularly with the use of anti-
androgenic progestin components.
The key mechanism of COC action is folliculogenesis 
inhibition through either suppression of pituitary gonadtoro-
phin secretion or direct inﬂ  uence on ovarian function when the 
COC agent has weaker anti-gonadotrapin activity. COC can 
also lead to a decrease in circulating albumin levels, leading 
to a decrease in dehydroepiandrosterone sulphate (DHEAS), 
which is strongly bound to albumin (Carlstrom et al 2002) 
and androgen production (Vrbikova and Cibula 2005) and a 
decrease in peripheral androgen production through an inhi-
bition of 5α reductase in the skin and a subsequent decrease 
in dihydrotestosterone levels (Cassidenti et al 1991). The 
combined effect is an overall decrease in gonadotropins and 
resulting androgens, which is a major goal of PCOS treatment. 
In addition, the estrogen component of COC increases sex 
hormone binding globulin (SHBG) production by the liver 
(Wiegratz et al 2003), which in turn reduces the circulating 
levels of free testosterone and its bioavailability.
One of the main issues in choosing COC for the treatment 
of PCOS is ﬁ  nding the most appropriate progestin component 
to provide the greatest anti androgenic effects. The criteria 
for oral contraceptive selection has not been thoroughly 
evaluated. It should be based on currently available clinical 
data, as well as on patient tolerance and response. Selection 
of a COC is based on 3 main variables: the type of estrogenic 
compound used, the type of progestin compound used, and 
the dosage of each when combined. In general, while the use 
of a monophasic compound may be preferred by the patient 
for its ease of use, the choice of a monophasic, biphasic or 
triphasic compound does not have any signiﬁ  cant effect on 
androgen production (Vrbikova and Cibula 2005). Today, the 
vast majority of COCs contain ethinyl estradiol (EE) as their 
estrogen, and thus only the type of progestin and the dosages 
of the steroids contained remain to be assessed.
Table 1 Clinical manifestations of polycystic ovary syndrome
Menstrual abnormalities (including oligo-amenorrhea, polymenorrhea, 
and dysfunctional uterine bleeding)
Excess facial and body terminal hair growth, and hirsutism
Seborrhea and acne
Alopecia
Obesity and central (visceral) fat distribution
Acanthosis nigricans and acrochordons
Polycystic ovaries
Modiﬁ  ed with permission from Azziz R, Nestler JE, et al eds. 2006. Androgen excess 
disorders in women, polycystic ovary syndrome and other disorders. 2nd ed. Totowa, 
New Jersey: Humana Press.Therapeutics and Clinical Risk Management 2008:4(2) 489
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The dose of EE varies between 15 and 50 µg, and 
the effects on the pituitary-ovarian axis occur in a dose 
dependent fashion. A daily dose of 30–35 µg of EE is 
appropriate for suppression of ovarian folliculogenesis in 
most women. EE is responsible for increasing circulating 
levels of SHBG Wiegratz (Wiegratz et al 2003). As a result, 
its overall androgenic potential is in part dependent on the 
progesterone it is combined with, and the progesterone 
effect on SHBG. Wiegratz and colleagues and van der 
Vange et al have shown that combining the same dose EE 
with different progesterone compounds resulted in signiﬁ  -
cantly different levels of SHBG (van der Vange et al 1990; 
Wiegratz et al 2003).
A number of different progestins are available in com-
bination oral contraceptives. Table 2 lists the most com-
mon progestins available and their androgenic proﬁ  les. 
Cyproterone acetate (CPA) is a commonly used progestin 
for the treatment of hirsutism in adolescence and beyond 
(Creatsas et al 2000), as it exhibits both progestogenic and 
signiﬁ  cant antiandrogenic properties. As all progestins, it 
inhibits LH, and subsequently the production of androgens 
by the ovarian theca cells, and increases the hepatic clearance 
of testosterone. It also competes at the receptor sites with 
androgens and thus exerts an antiandrogenic inﬂ  uence. We 
should note that the amount of CPA present in COC (2 mg) 
exerts a modest effect on hirsutism, and often the addition 
of higher doses of the steroid (12.5–80 mg/day) are required 
for maximum suppression of hair growth (Hammerstein 
et al 1975; Barth et al 1991). CPA also demonstrates mild 
anti-glucorticoid effects which may become more apparent 
at higher doses.
A newer form of progestin, drospirenone, has been 
recently introduced, and is marketed as part of a COC 
(Yasmin® and Yaz® in the United States), in combination with 
EE. The next section of this article will focus on the progestin 
drospirenone, and its use in patients with PCOS.
Drospirenone – a progestin 
with differences
Drospirenone, in conjunction with EE, acts to suppress 
gonadotropins. This is achieved through inhibition of ovula-
tion as described above. Drospirenone has a bioavailability 
of 76% with approximately 20% excreted through the feces, 
and 45% through the renal system. The half-life of drospire-
none is 30 hours, which is slightly longer than the half-life 
of EE (24 hours).
Drospirenone differs from other progestins currently 
available in other COC compounds, as it exhibits both 
mineralocorticoid effects and antiandrogenic effects. Part 
of the novel nature of drospirenone stems from it being 
structurally and functionally analogous to spironolactone 
(Figure 1). Spironolactone is an aldosterone antagonist, 
and a potassium-sparing diuretic. Because of this structural 
and functional similarity with spironolactone, drospirenone 
also exhibits anti-mineralocorticoid activity. This property 
counteracts the estrogen stimulated activity of the renin-
angiotensin-aldosterone system, which can inﬂ  uence the 
regulation of water and electrolyte balance. Because of the 
possibility that potassium levels may increase, drospirenone 
should not be used in patients with kidney, liver or adrenal 
Figure 1 Structure of drospirenone (1a) and spironolactone (1b).
Table 2 Currently available progestins and their androgenic 
effects
Progestin Androgenic  effect
Levonorgestrel High
Norgestrel High
Norethindrone   Medium
Norethindrone acetate  Medium
Ethynodiol diacetate  Low
Norgestimate None
Desogestrel None
Drosperinone AntiandrogenicTherapeutics and Clinical Risk Management 2008:4(2) 490
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disease. In addition, any patient on other medications that can 
raise potassium levels (such as ACE inhibitors, angiotensin II 
receptor antagonists, NSAIDS, potassium-sparing diuretics, 
and heparin) should be cautioned. This anti-mineralocorticoid 
activity may also contribute to less water retention as well 
as less breast swelling and tenderness in women using this 
form or progestin compared to others. Preclinical studies in 
animals and in vivo have shown that drospirenone has no 
androgenic, estrogenic, glucocorticoid or anti-glucocorticoid 
activity (product monograph). Preclinical studies have 
shown anti-androgenic activity. Due to its anti-androgen 
effect, drospirenone can also be used as adjunct treatment 
for hirsutism, and may be a progestin of choice in women 
who complain of excessive hair growth.
Drospirenone in combination 
with EE
Drospirenone is taken orally in preparations with EE. At present, 
2 combinations are available for use in the United States: 1) 
Yasmin® containing 3 µg of drospirenone in combination with 
30 µg for EE per tablet; and 2) Yaz® which contains 3 µg of 
drospirenone and 20 mcg of EE per tablet. As a note, it is 
also available in a preparation to manage post-menopausal 
symptoms. Angeliq® was approved by the US FDA for oral 
use at a dose of 0.5 µg drospirenone per day combined with 
1 µg estradiol for treatment of menopausal symptoms.
Adverse effects may include a change of weight, increase 
in migraine activity, depression, and nausea. As with most 
COC there may also be breast swelling and tenderness 
(though usually to a lesser extent as discussed previously) 
as well as break-through-bleeding. In addition to the spe-
ciﬁ  c drug interactions mentioned above related to the anti-
mineralocortcoid effect, the same interactions should be 
considered as with the use of any COC. These include but are 
not limited to interactions with antipsychotics, cyclosporins, 
dilantin, steroids, and rifampin.
As with all COC this medication is contraindicated in 
patients with hepatic dysfunction, and in those who smoke 
and those who have a history of coagulopathy, DVT or stroke. 
Other contraindications for the use of COC also apply to 
the products containing drospirenone such as carcinoma of 
the breast or endometrium, and undiagnosed genital bleed-
ing. Patients over the age of 35 may also be at higher risk 
or complications such as thrombophlebitis and should be 
cautioned as such. The use of drospirenone in premenstrual 
women is not approved.
When drospirenone in combination with 30 µg of EE per 
tablet is compared to 3 µg of drospirenone in combination 
with of EE per tablet, the latter may have less of a hemostatic 
impact (Kluft et al 2006).
Drospirenone and PCOS
COCs containing drospirenone are a viable and potentially 
preferred option for use in the treatment of PCOS and its 
related symptoms. The efﬁ  cacy of COCs containing drospi-
renone as the progestin agent has recently become the topic 
of much study. Drospirenone has proven to be effective in 
decreasing hirsutism and testosterone levels and, more sig-
niﬁ  cantly, increasing sex hormone binding globulin (SHBG) 
levels in women who have PCOS.
Pehlivanov and Mitkov performed an open study in 
which 20 women with PCOS (Rotterdam criteria 2003) were 
enrolled (Pehlivanov and Mitkov 2007). All women received 
30 µg EE and 3 mg drospirenone (DRSP) on the ﬁ  rst day of 
menstruation. The pill regimen was followed for six cycles. 
The 6-month regimen did result in some signiﬁ  cant improve-
ments in PCOS symptomatology and hormone levels. 
Hirsutism was signiﬁ  cantly decreased as demonstrated by a 
signiﬁ  cant decrease in F-G score from baseline. Addition-
ally, testosterone levels decreased signiﬁ  cantly and SHBG 
level increased signiﬁ  cantly. These two changes also resulted 
in a signiﬁ  cant decrease in the Free Androgen Index of the 
enrolled women. Overall, this study demonstrated that COCs 
with DRSP are effective in decreasing hyperandrogenemia 
and reducing hirsutism (a primary symptom of PCOS).
Guido et al also investigated the effects of a drospirenone-
containing COC in the treatment of PCOS with 18 subjects 
and 12 cycles of the COC (Guido et al 2004). Similar to 
Pehlianov and Mitkov, Guido and colleagues observed 
a signiﬁ  cant decrease in hirsutism as demonstrated by a 
signiﬁ  cant decrease in F-G score. This decrease was not seen 
by the third cycle but was evident at both the 6th cycle and 
the 12th cycle. These authors conﬁ  rmed the previous ﬁ  nding 
that drospirenone-containing COC does decrease hirsutism in 
women with PCOS. Guido also noted a signiﬁ  cant increase 
in SHBG at the 3rd cycle, 6th cycle, and 12th cycle. This 
indicates that the increase in SHBG occurs soon after the 
administration of the drospirenone-containing COC and that 
it is a long-lasting rather than transient effect. Guido’s results 
also supported the signiﬁ  cant decrease in testosterone found 
by both Pehlianov and Mitkov, and De Leo and colleagues. 
These authors noted that the size of the SHBG increase found 
with drospirenone-containing COC treatment was greater than 
that found with treatment using 17α-hydroxyprogesterone 
derivatives. This indicates that drospirenone-containing COCs 
may be more effective in the treatment of hyperandrogenemia Therapeutics and Clinical Risk Management 2008:4(2) 491
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than COCs that use 17α-hydroxyprogesterone derivatives 
as the progestin agents (Guido et al 2004). A similar study 
conducted by Batukan and Muderris corroborated these 
results. Drospirenone-containing COCs were found to 
signiﬁ  cantly increase SHBG levels, signiﬁ  cantly decrease 
testosterone levels, and signiﬁ  cantly improve hirsutism after 
12 cycles (Batukan and Muderris 2006).
Overall, drospirenone-containing COCs appear to be 
effective in treating and alleviating the symptoms of PCOS. 
Numerous studies show a decrease in hirsutism within as few 
as six cycles of drospirenone-containing COCs. Studies have 
also consistently demonstrated a decrease in testosterone 
levels within six cycles and an increase in SHBG in as few 
as six cycles on therapy. There is also evidence that treatment 
with a drospirenone-containing COC decreases the severity 
of acne in women with PCOS (Palep-Singh et al 2004). Thus, 
drospirenone-containing COCs are as effective at treating 
PCOS and its symptoms as other COCs. This could poten-
tially make them more effective in the treatment of PCOS 
than the traditional COCs.
Metabolic concerns
More recently, controversy has arisen over the use of COC in 
patients with PCOS (Nader and Diamanti-Kandarakis 2007) 
speciﬁ  cally regarding the effects of COCs on carbohydrate 
metabolism and metabolic parameters such as insulin resis-
tance and glucose tolerance (Korytkowski et al 1995; Nader 
and Diamanti-Kandarakis 2007). The most signiﬁ  cant change 
found is a deterioration of insulin sensitivity with the admin-
istration of COCs (Korytkowski et al 1995; Dahlgren et al 
1998). Two studies conducted in obese women with PCOS 
also showed a decrease in glucose tolerance demonstrated 
by the results of an oral glucose tolerance test (Nader et al 
1997; Morin-Papunen et al 2000). Plasma insulin concen-
trations were constant in both of these studies indicating 
that the decrease in glucose tolerance was again due to a 
decrease in insulin sensitivity rather than a change in insulin 
levels/production. However, other studies performed in non-
obese women showed no change in glucose tolerance and 
insulin sensitivity (Armstrong et al 2001; Cibula et al 2002; 
Elter et al 2002; Morin-Papunen et al 2003). This variation 
in results may suggest that metabolic consequences from 
COC treatment of PCOS depend on body type (Vrbikova 
and Cibula 2005).
COC treatment of PCOS also has been shown to cause an 
increase in total cholesterol, triglycerides, HDL and LDL cho-
lesterol (Creatsas et al 2000; Mastorakos et al 2002; Cibula 
et al 2005). The opposite ﬁ  nding, however, has been reported 
with COCs containing the same progestin resulting in an 
overall decrease in the LDL:HDL ratio (Falsetti and Pasinetti 
1995). Triglycerides and HDL cholesterol did increase in both 
studies however. While cholesterol levels appear to increase 
in women with PCOS who are treated with COCs regardless 
of the COC used, desgetrel containing COCs do not seem 
to cause changes in triglyceride levels while other COCs do 
(Escobar-Morreale et al 2000; Mastorakos et al 2002).
The metabolic effects of drospirenone-containing COCs 
are just beginning to be explored. The European Active 
Surveillance Study on oral contraceptives followed 58,674 
women for a total of 142,475 women years of observation and 
concluded that the risks of adverse cardiovascular disease and 
other serious events in users of drospirenone-containing oral 
contraceptives are similar to those associated with the use of 
other COCs (Dinger et al 2007). Because drospirenone is a 
less androgenic progestin, the metabolic effects appear to be 
much less severe or entirely non-existent when women with 
PCOS are treated with drospirenone-containing COCs. Guido 
found no signiﬁ  cant change in insulin sensitivity in a study 
of 15 PCOS women treated with drospirenone-containing 
COCs (Guido et al 2004). The same study also found that 
drospirenone-containing COCs appear to have the same 
effect on lipid levels of PCOS women that they do on healthy 
controls, which is a major improvement from other COCs. 
A signiﬁ  cant increase in triglycerides and HDL cholesterol 
has been observed but with no shift in the HDL:LDL ratio 
(Guido et al 2004). Thus, although the metabolic concerns 
typical of COC administration in healthy women still exist 
when drospirenone-containing COCs are used in the treatment 
of PCOS, the use of drospirenone appears to alleviate the 
metabolic concerns that are speciﬁ  c to women with PCOS.
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